Atreca cuts lead asset, 40% of workforce

11 Aug 2023
www.pharmamanufacturing.com
ImmunotherapyADC
California-based immunotherapy biotech Atreca has announced its second corporate reorg in recent history, with the goal of reducing expenses and extending its cash runway.
Atreca's cost-saving measures will include suspending development of its lead asset, ATRC-101, and reducing its workforce by approximately 40%.
The company recently shared data from the ongoing phase 1b study of ATRC-101 in patients with select advanced solid tumors, supporting the asset's observed safety and tolerability profile as well as the correlation between longer progression-free survival and high target expression. Now, according to Atreca CEO, the asset is now available for purchase. "We believe that the best path forward for the asset is with a larger partner, and as a result, we are suspending development and evaluating potential out-licensing opportunities."
Atreca's plan going forward is to instead focus on advancing current preclinical ADC candidates, including APN-497444. The move comes as ADCs experience an explosive renaissance, ripe with licensing deals and big-ticket acquisitions. The early-stage APN-497444 program is an Atreca-discovered antibody targeting a novel, tumor-specific glycan. Atreca is targeting an IND submission in late 2024/early 2025.
This is the second major reorg initiated by Atreca recently. Last June, the biotech reduced its workforce by more than 25% in an effort to extend its cash runway through 2023.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.